Vallerie McLaughlin, Richard N Channick, Hossein-Ardeschir Ghofrani, Jean-Christophe Lemarié, Robert Naeije, Milton Packer, Rogério Souza, Victor F Tapson, Jonathan Tolson, Hikmet Al Hiti, Gisela Meyer, Marius M Hoeper
The safety and efficacy of adding bosentan to sildenafil in pulmonary arterial hypertension (PAH) patients was investigated.In this prospective, double-blind, event-driven trial, symptomatic PAH patients receiving stable sildenafil (≥20 mg three times daily) for ≥3 months were randomised (1:1) to placebo or bosentan (125 mg twice daily). The composite primary end-point was the time to the first morbidity/mortality event, defined as all-cause death, hospitalisation for PAH worsening or intravenous prostanoid initiation, atrial septostomy, lung transplant, or PAH worsening...
August 2015: European Respiratory Journal